genomic determinants of resistance in patients with ndmm treated with targeted immunotherapy
Published 1 year ago • 63 plays • Length 3:26Download video MP4
Download video MP3
Similar videos
-
1:05
using machine learning to predict the outcomes of patients with ndmm being treated with vrd
-
1:52
single-cell and immune sequencing to predict response and resistance to car-t therapy in r/r mm
-
3:02
novel treatments and ongoing clinical trials for wm: targeted agents and immunotherapies
-
0:52
genomic profiling at diagnosis of myeloid neoplasms
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
3:43
genomic profiling to predict prognosis for patients with hr-smm
-
4:13
benefit trial: isatuximab, lenalidomide, and dexamethasone /- bortezomib in newly diagnosed myeloma
-
2:57
novel targeted therapies for the treatment of bpdcn
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:38
the genomic definition of high-risk myeloma
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:12
ongoing research exploring mechanisms of resistance to imids in myeloma
-
4:01
the latest genomic updates in the field of mds
-
1:49
genomic advancements in non-malignant hematology
-
1:57
combining molecular and clinical data to predict survival & transformation risk in patients with mds